The Addition of DPP4-Inhibitors to Metformin Therapy in the Long-term Management of Type II Diabetes Mellitus by Smith, Jill
University of North Dakota
UND Scholarly Commons
Nursing Capstones Department of Nursing
4-19-2017
The Addition of DPP4-Inhibitors to Metformin
Therapy in the Long-term Management of Type II
Diabetes Mellitus
Jill Smith
Follow this and additional works at: https://commons.und.edu/nurs-capstones
This Independent Study is brought to you for free and open access by the Department of Nursing at UND Scholarly Commons. It has been accepted for
inclusion in Nursing Capstones by an authorized administrator of UND Scholarly Commons. For more information, please contact
zeineb.yousif@library.und.edu.
Recommended Citation
Smith, Jill, "The Addition of DPP4-Inhibitors to Metformin Therapy in the Long-term Management of Type II Diabetes Mellitus"
(2017). Nursing Capstones. 147.
https://commons.und.edu/nurs-capstones/147
Running head: THE ADDITION OF DPP4-INHIBITORS 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Addition of DPP4-Inhibitors to Metformin Therapy in the Long-term  
 
Management of Type II Diabetes Mellitus 
 
Jill Smith 
 
University of North Dakota  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE ADDITION OF DPP4-INHIBITORS   
 2 
 
 
PERMISSION 
 
Title The Addition of DPP4-Inhibitors to Metformin Therapy in the Long-term 
Management of Type II Diabetes Mellitus 
 
Department  Nursing 
Degree  Master of Science 
 
In presenting this independent study in partial fulfillment of the requirements for a graduate 
degree from the University of North Dakota, I agree that the College of Nursing of this 
University shall make it freely available for inspection. I further agree that permission for 
extensive copying or electronic access for scholarly purposes may be granted by the professor 
who supervised my independent study work or, in her absence, by the chairperson of the 
department or the dean of the Graduate School. It is understood that any copying or publication 
or other use of this independent study or part thereof for financial gain shall not be allowed 
without my written permission. It is also understood that due recognition shall be given to me 
and to the University of North Dakota in any scholarly use which may be made of any material 
in my independent study. 
 
 
 
 
Signature ____________________________ 
 
 
Date _____________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE ADDITION OF DPP4-INHIBITORS   
 3 
Abstract 
 
This paper explores dipeptidyl peptidase-4 (DPP-4) inhibitors as an additional treatment 
option for patients with type II Diabetes Mellitus (DM) who are not controlled with 
metformin.  The purpose is to look at the research indicating the efficacy and benefits of 
utilizing a DPP-4 inhibitor as an oral method for management of type II DM.  Many patients 
with type II DM are often resistant to use an injectable medication, like insulin as part of 
their treatment plan. Many would like to continue to treat their diabetes with oral 
medications and the use of DPP-4 inhibitors may make that possible.  Current studies look 
at the preservation of beta cell function and improved insulin sensitivity with the use of 
DPP-4 inhibitors, as well as the ability to effectively manage type II DM without insulin 
therapy (Utzschneider et al., 2017).  By utilizing the DPP-4 inhibitors, the hope is to be able 
to offer this patient population a safe and effective way to manage their diabetes while 
prolonging the transition and possibly avoiding the need for insulin therapy.  
Background 
D. is a 60 year old Caucasian female who came to the clinic with a history of 
hypertension, hyperlipidemia, and type II DM.  She was diagnosed with type II DM 
approximately 10 years prior.  She has been managed on 500mg of Metformin twice daily.  
She was unsure of what her previous Hemoglobin (Hgb) A1C had been in the past.  In the 
clinic, it was found that her DM was no longer controlled with a single oral medication and 
an adjustment would have to be made in order to improve her long-term health.  This 
patient was willing to transition to insulin therapy if advised, which often times is not the 
case for diabetic patients.   
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There are other oral treatment options aside from metformin for individuals who 
are unable to or are not ready to transition to insulin or other injectable therapy while 
managing their diabetes.  The option that will be addressed in this paper includes the use of 
DPP-4 inhibitors.  DDP-4 inhibitors have been found not only to control blood sugars, but 
also to slow the decline of the beta cell function; which has been found to begin even prior 
to ones diagnosis of DM (Croxtall & Keam, 2008). DPP-4 inhibitors have shown to not be as 
effective as Metformin in terms of lowering Hgb A1C; however they have been found to be 
very effective as a combination therapy (Croxtall & Keam, 2008).  Metformin tends to work 
in many different areas in the physiologic process of diabetes. These mechanisms include 
decreasing hepatic glucose production and intestinal absorption as well as increasing the 
peripheral glucose uptake and utilization (Woo & Robinson, 2016).  Metformin is often 
utilized as first line therapy because of the efficacy it has in lowering the Hgb A1C, 
decreasing weight, and it’s positive effect on lipid levels (Woo & Robinson, 2016).  If the 
goal of the patient is to utilize oral agents for as long as possible and the patient is not 
achieving their Hgb A1C goal with Metformin alone, the DPP-4 inhibitor drug class may be 
an option.  
Monotherapy with any oral medication is often unsuccessful in managing patient’s 
long term with type II diabetes (Yoon et al., 2011). Yoon et al. (2011) state that the biggest 
drawback to starting a patient on a single oral medication is that while titrating oral 
dosages, patients are exposed to prolonged periods of hyperglycemia.  This predisposes 
them to an increased risk of vascular disease.  Initiating a combination therapy at the time 
of diagnosis will get a higher proportion of patients to goal versus the initiation of 
monotherapy (Yoon et al., 2011).   A better long term management of diabetes will help 
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sustain the beta cell function in an individual, therefore increasing the efficacy of oral 
treatments as well as decreasing the chronic effects of diabetes such as neuropathy, 
retinopathy, and cardiovascular events. 
Case Report 
D. was in to the clinic on 3/10/2017 with the chief complaint of acute fatigue. She 
had been in the diabetic educator’s office the week prior who suggested she be seen by 
primary care.  She was last seen by her primary care providers about six months ago and 
states she is seen on a yearly basis.  She has a history of hyperlipidemia, hypertension, and 
type II DM.  She reported it has been 10 years since she was first diagnosed with diabetes.  
She has no neuropathy complaints; she gets annual eye exams and states that her primary 
will do yearly foot exams.  She does not personally examine her feet nor was taught to do 
so. D.’s diabetes was managed with 500mg Metformin twice daily, her hypertension is 
managed with Lisinopril 20mg daily, her hyperlipidemia is managed with 20mg 
Atorvastatin daily and she also takes 81mg aspirin daily as well as a daily multivitamin.  
She is allergic to Penicillin; the specific reaction was not noted.  She reported never having 
smoked or been around second hand smoke in the home.  D. stated that she generally 
checks her blood sugar twice a week and noticed that it had been running between 150-
200mg/dL.  D. reported sleeping well, feeling refreshed in the morning and was not aware 
of any snoring or apnea.  D. also denied any recent weight gain or constipation.  
D.’s physical exam revealed good blood pressure control at 120/80 and a pulse of 64 
beats per minute.  She was afebrile and reported no recent fevers or chills. Her neck was 
supple; no masses were felt.  She has a regular heart rhythm, no murmurs or rubs, and a 
normal respiratory effort without any crackles or wheezes present upon auscultation.  Her 
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abdomen was soft, non-tender and bowel sounds present in all four quadrants.  There was 
no lymphadenopathy felt; she was alert and orientation x4, skin was warm, dry, no 
abrasions, rashes, or lesions noted.  She was noted to have full range of motion in all 
extremities and she had a normal mood and affect.  When doing her foot exam, she had 
good sensation in all areas. She had no breakdown or callousing noted and good skin 
condition between joints and phalanxes.  
To assist in the management and diagnosis for the etiology of her fatigue, it was 
decided to obtain some diagnostic lab work.  A complete blood count was ordered to look 
for anemia, a comprehensive metabolic count was ordered to assess electrolyte imbalances, 
fasting blood glucose, and hydration status.  A Hgb A1C was ordered to assess her overall 
management of diabetes in approximately the past three months.  Due to her 
hyperlipidemia and the possible long terms effects due to her comorbidities; a fasting lipid 
panel was drawn. This will help assess for the need for lifestyle or medication changes.  
Lastly, a thyroid stimulating hormone was drawn to assess for thyroid function.  If her 
thyroid was not producing enough hormone; it could help to diagnosis a deficiency and 
point to a possible source for her fatigue.  
The only lab that was out of normal limits was her Hgb A1C at 8.3%.  According to 
Cefalu (2017), the goal is somewhere between 6.5% and 7% depending on the patient and 
the practitioner.  D.’s Hgb A1C indicated that her diabetes mellitus was in an uncontrolled 
state.  Since she was diagnosed with diabetes 10 years prior and has been on an oral 
antihyperglycemic agent, lifestyle choices and changes were reinforced but were unable to 
be the sole intervention.  At this point in her care, it was important to discuss what she 
would like to include in her pharmacological management.  She was given the option of 
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either pursuing another oral medication or starting a basal rate of insulin.  Due to her 10 
year history of diabetes, her age of 60 years and her fairly elevated Hgb A1C of 8.3%; a 
basal insulin was encouraged, but the decision was ultimately left up to the patient.  D. was 
very receptive to starting a basal rate of insulin and decided that she was open to the 
lifestyle changes associated with it. 
 D. was instructed to continue her same medication management, including the 
metformin, but she now will add in a nightly insulin injection of Glargine.  She will start 
with a dose of five units nightly and increase it by one unit every two days if her blood 
sugars continue to be above 150mg/dL.  It was also asked that she check her blood sugar 
twice daily, once in the morning and once in the evening and to keep a log of her results 
with pertinent information.  This included different snacks, meals, and/or exercise that 
may have affected her glucose.  She will plan to return to the clinic in 1 week for a re-
evaluation of her management and a possible adjustment of her insulin.  A large portion of 
this visit was centered around education in using the insulin pens, effects of insulin, signs 
and symptoms of hypoglycemia as well as how to handle low blood sugars.  She was given 
an instruction sheet with a summary of the visit, a plan of care and how to take her insulin 
and titrate it up to goal.  All her questions were answered and she was given the clinic 
phone number to call if any questions arise so that she can talk to the nurse or myself for 
instructions.  She was also advised to follow up with her primary care at least every three 
months for now while managing her diabetes; if she would like to establish with myself for 
management she was encouraged to do so.  She was instructed on “red flag” symptoms and 
to return to the clinic sooner with any acute changes or new concerns.  Please refer to 
Appendix A for the full progress note.  
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Literature Review 
Type II DM is a chronic disease that involves glycemic control, but also involves 
managing comorbidities such as hypertension, obesity and dyslipidemia (Kasper et al., 
2014).  Obtaining control of diabetes is very important to prevent damage to organs that 
are necessary for living such as the kidneys.  While some individuals are very receptive and 
open to starting insulin like in D.’s case, others are not and an acceptable and effective 
alternative treatment plan should be offered and utilized.  It is important to consider the 
individual’s own physiologic ability to either make insulin or be receptive to it. 
When looking at the pharmacological management of this disease, it is important to 
consider the physiological process that is taking place.  DM type II involves a decreased 
sensitivity to endogenous insulin as well as degradation of the beta cell function.  This is 
key in producing the insulin that is needed to drive the glucose into the body’s cells (Kasper 
et al., 2014).  Mu et al. (2006) observed that a class of medications, the DPP-4 inhibitors, 
works as a key regulator in the incretin hormones.  Incretins work in response to a meal by 
stimulating insulin production and glucagon release, decreasing gastric emptying and 
increasing satiety.  These advantageous incretin hormones are ultimately destroyed by 
dipeptidyl peptidase-4.  By utilizing DPP-4 inhibitors, we are able to slow incretin 
degradation, and ultimately increase mealtime insulin production, glucagon release, and 
satiety.  This will in turn decrease the overall blood glucose of an individual (Aschner et al., 
2006). 
While it may not be traditionally done, DPP4-inhibitors have the possibility of being 
utilized as a first line treatment in type II DM.  Aschner, P. et al. (2006) looked at utilizing 
the DPP-4 inhibitor class as a monotherapy.  It was noted that a once daily dose of 
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Sitagliptin (DPP-4 inhibitor) of at least 100mg inhibited plasma activity of the DPP-4 
hormone by greater than 80%.  That equates to an increase of two to three times more 
active incretin hormone, increased insulin and decreased plasma glucose.  By blocking the 
hormones that lower insulin production and glucose release, there is an ability to decrease 
the plasma glucose levels.  This works primarily on post parandial glucose management, 
which will help decrease an individual’s susceptibility to hypoglycemia episodes while on 
this medication.  Orally administered DPP4-inhibitors alone can decrease a hemoglobin 
A1C by 0.5%-1.0% (Drucker & Nauck, 2006).  For those who need more of a decrease to 
obtain a goal Hgb A1C, one might need an additional therapy.  While it is not yet supported 
in literature to utilize the DPP-4 inhibitors as first line monotherapy; it might be a 
medication that is utilized in the future for those who are unable to tolerate the use of 
metformin for various reasons. 
The most common agent to combine DPP4-inhibitors with is metformin.  This is the 
current standard of care (American Diabetes Association, 2017).  Patients are commonly 
started on metformin as monotherapy when they start to show signs and symptoms of type 
II DM and their Hgb A1C is above 6.5%.  As their Hgb A1C starts to rise, their dose of 
Metformin will be increased as tolerated until their diabetes is controlled, or until they 
reach a maximum dose of 2550 mg per day (Woo & Robinson, 2016).  When additional 
intervention is needed to control their hyperglycemia, supplementary treatment options 
are looked at.  Insulin therapy may not appeal to a diabetic patient, especially in the early 
stages of treatment.  It is now being found that earlier treatment can possibly prevent or 
minimize the loss of beta cell function. (Mudaliar, S., 2013).  Undoubtedly lifestyle changes 
are the preferred way to prevent type II DM.  While some people are able to treat or control 
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their DM2 this way, for others additional treatment or intervention is needed.  It is possible 
that starting individuals on a dual therapy early in their treatment for diabetes is beneficial.  
Yoon et al. (2011) state that an initial combination therapy may have a greater benefit on 
the B-cell function and help an individual maintain a long-term glycemic control without 
insulin.  By utilizing two different antihyperglycemic agents, you will target different 
physiological processes and therefore be more effective at lowering the plasma glucose 
level.  In utilizing a DPP-4 inhibitor you will increase the amount of active incretin 
hormones in the body. The DDP-4 inhibitor drug class has been shown to have an apoptotic 
and pro-proliferative effects on the B-cells.  Another class of antihyperglycemics, the 
thiazolidinediones, have an agonistic effect on receptors and have been shown to increase 
B-cell structure and their ability to function as well as increasing the hepatic glucose output 
and decreasing the insulin resistance.  Through this method you might be able to utilize the 
complimentary actions of oral agents and achieve a target Hgb A1C more effectively.  
It is known that certain risk factors pre dispose some people to type II DM such as 
physical inactivity, first degree relatives with type II diabetes, certain ethnic groups, 
hypertension, hyperlipidemia, polycystic ovarian syndrome, and a history of cardiovascular 
disease (American Diabetes Association, 2017).  There also are screening guidelines as 
well, which is secondary prevention.  The American Diabetes Association (2017) 
recommends that fasting blood glucose screening should begin at age 45 and if results are 
normal, testing should be repeated every three years. What experts are not as concrete on 
is what occurs physically during the prodromal period of development of diabetes. How 
early or how late before diagnosis does the beta cell function start to decline?  Would 
treatment with a DPP4-inhibitor before diagnosis (those with a high enough risk) benefit?  
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If this process can be identified, medication therapy can potentially be utilized to prevent 
or prolong the development of type II DM with early recognition.  An article by Tabak et al. 
(2009) attempted to look at the pathological process and timing of impaired glucose 
tolerance, insulin sensitivity, and insulin secretion in type II diabetes.  These individuals 
found that beta cell function has an abrupt and short-lived elevation between years three 
and four prior to the diagnosis of type II DM.  After that small spike in productivity, the 
function of the beta cells begins to decrease and hyperglycemia becomes evident.  This will 
continue until a diagnosis of type II DM is made.  Knowing this trend, it is possible that in 
the future this will be a target for therapy in the prevention or prolongation of type II 
diabetes. 
 Important to include in consideration for treatment in an individual with type II 
diabetes is the degree of exhaustion in the beta cells.  While our case study, D., was 
diagnosed with diabetes 10 years prior, her beta cell function most likely started the 
decline about 13 years ago.  She made the choice to begin injection therapy with insulin, 
which was encouraged by her practitioner.  While the DPP-4 inhibitor is another option 
and one that is worth a try, you may not see as good of results as with insulin due to the 
possible exhaustion of her beta cells.  
Some of the attractions to using a DPP-4 inhibitor in patients are that they 
essentially work to augment a natural hormone or process that already exists.  Many times 
synthetic products are created that are suitable for pharmacological therapy. The downside 
is that they may have multiple side effects or interactions.  The DPP4-inhibitors tend to not 
have many side effects due to this natural augmentation. There can be some 
gastrointestinal side effects such as nausea and vomiting, but these side effects do tend to 
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recede after therapy has been stabilized.  The most important thing to remember is to start 
low and go slow with titration (Svec, 2010).  Another side effect that should be recognized 
is unexplained joint aches and pains.  These can occur at the start of treatment or 
unprecedented a year later.  According to Lowes (2015), this pain will recede within a 
month of cessation of the medication.  With a DPP4-inhibitor, the degradation of DPP-4 is 
prevented.  It is theorized that through this mechanism, another enzyme that degrades 
something in the inflammatory process is inhibited, therefore leading to these aches and 
pains.  Zhong et al. (2015) reported that the DPP-4 enzyme may affect cardiovascular 
function through the regulation of inflammation.  The authors state that the DPP-4 enzyme 
is highly present on many of the inflammatory cells, such as the T cells, and that it generally 
will control their function.  In some individuals, inhibition of this enzyme may cross over to 
their joints and cause pain as a side effect.  While D. does not have any rheumatologic 
concerns or chronic pain, individuals that do have these comorbidities may not be 
appropriate candidates for this choice of therapy.  
Diabetes has multiple complications, one of them being cardiovascular disease.  
Because of this, Nga et al. (2011) researched the effects that DPP4-inhibitors have on the 
cardiovascular system.  It was found that DPP-4 inhibitors reduced the amount of 
atherosclerotic lesions that were present in diabetic mice.  The importance of this finding is 
that while utilizing DPP4-inhbitors to manage diabetes, atherosclerotic lesions are being 
reduced, and therefore the amount of diabetic complications is decreased.  
When examining the effect that DPP-4 inhibitors have on the development of 
atherosclerotic plaques, it does make sense that individuals who have higher levels of 
incretin hormones in the body tend to have lower levels of cardiovascular disease.  
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Matsbubara et al. (2012) state that DPP-4 inhibitors work to phosphorylate the nitric oxide 
produced by the epithelium and therefore reduce the amount of atherosclerosis that 
accumulates over time and in diseased states.  This process is one of the main components 
in diabetic complications, and many individuals tend to face multiple comorbidities that 
put them at high risk.  In the case study of D., it would be ideal to utilize a DPP-4 inhibitor to 
not only manage her hyperglycemia but also to combat her comorbidities of hypertension 
and hyperlipidemia.  Reducing atherosclerotic plaques in her vasculature system will help 
to reduce the progression of her comorbidities as well as prevent the development of other 
complications such as small vessel disease in the form of neuropathy, nephropathy, or 
retinopathy.  
Learning Points 
• DPP4-inhibitors are starting to be studied as a monotherapy agent in the control of 
diabetes. They have not been found to be more effective than metformin, however they 
may be an alternative if metformin is not an option.  
• Dual therapy with two oral agents earlier in treatment may better effectively manage 
diabetes and prolong the time until insulin is needed.  
• While beta cell function has been found to decline about three years prior to diagnosis 
of diabetes, DPP4-inhibitors have been found to increase the function of the beta cells 
as well as reduce the amount of apoptosis that occurs.  
• An attraction to DPP-4 inhibitors over other pharmacological interventions is that they 
augment a natural process instead of utilizing a synthetic product. They are also weight 
neutral, they have a low propensity for hypoglycemia, and they have a low interaction 
rate with other medications.  
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• DPP-4 inhibitors affect on the cardiovascular system by reducing the amount of 
atherosclerosis present. They work to phosphorylate the nitric oxide and stabilize the 
epithelium that is preset in the vasculature. This should decrease and prolong the 
diabetic associated comorbidities such as hypertension and hyperlipidemia.  
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Appendix A 
 
Progress Note for D. 
 
CC 
D. is a 60yr of female who presents today for diabetes recheck. She saw her diabetes 
educator last week and was encouraged to follow up in the clinic.  
 
HPI 
D. is a new patient who presents today for a follow up on diabetic care. She saw her 
diabetic educator approximately 1 week ago who encouraged her to schedule a follow up in 
the clinic. She reports that her last follow up with her primary was about 6 months ago and 
that she is seen in the clinic on a yearly basis for management. She states that she has been 
a diabetic for about 10 years and has been “well managed” during that time period. She 
states she does get annual eye exams and her most recent was in May 2016. She does not 
routinely examine her feet but states that her primary does this during her yearly visits.  
She does report checking her sugars about twice a week and they are currently running 
anywhere between 150-200mg/dL. She does not check them at a consistent time during 
the day. She is not a smoker, she is not exposed to second hand smoke, nor has she ever 
smoked in the past. Currently her only symptom that she has noticed recently, is she is 
more fatigued. She reports sleeping well, feeling refreshed in the morning, and does not 
report any observed snoring or apnea. She is unaware if she has ever had her thyroid 
checked; however she denies any recent weight gain, or constipation.  
 
Medications 
Metformin 500mg twice daily 
Aspirin 81mg daily 
Lisinopril 20mg daily 
Atorvastatin 20mg daily 
Multivitamin daily 
 
Allergies 
Penicillin 
 
PMH/Problem List 
Dyslipidemia, Hypertension, Diabetes Mellitus type 2 
 
Social History 
D. lives independently in a private home with a significant other. She continues to have a 
job where she works 40 hours a week. She does have living children.  
 
ROS 
See HPI 
 
Physical Exam 
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BP   120/80  Pulse  64  Temp 98.3  SpO2  90% on Room Air 
 
Constitutional: Patient is well groomed, in no acute distress, does not appear ill. 
HENT: Head normocephalic, atraumatic, nasal mucosa pink, no septal deviation, no 
rhinorrhea, oropharynx clear and moist, posterior pharynx without edema or exudate 
Eyes: PERRLA, conjunctivae without injection, no discharge 
Neck: supple, no masses, trachea midline 
Cardiovascular: Regular rhythm, S1 and S2 normal. Exam reveals no S3 or S4. No murmur, 
rubs, or gallop. Brisk capillary refill. No peripheral edema. 
Pulmonary/Chest: Effort normal, symmetric unlabored respirations, no respiratory 
distress, no crackles or wheeze, no chest tenderness 
GI: soft, non-tender to palpation, bowel sounds present x4, no splenomegaly 
Lymphadenopathy: No retropharyngeal, submental, submandibular, preauricular, post 
auricular, cervical, occipital, or supraclavicular lymphadenopathy appreciated. 
Neurological: Alert and oriented x 3 
Skin: Warm and dry, no abnormal lesions or rashes 
Musculoskeletal: full range of motion without pain 
Psychiatric: Normal mood and affect. 
 
Differential Diagnoses 
Hypothyroidism  
Sleep Apnea 
Uncontrolled Diabetes Mellitus type 2 
 
Lab data/Diagnostics 
CMP unremarkable 
CBC unremarkable 
Fasting Lipid Panel unremarkable 
TSH unremarkable 
Hgb A1C = 8.3 
 
Course/Plan 
Diagnostics ordered as above 
 
A discussion was had with D. concerning her lab data and diagnostics. Her tests were 
unremarkable aside from an elevated Hgb A1C at 8.3. Her current medication regimen of 
Metformin 500mg BID is no longer controlling her diabetes mellitus type 2. She was 
educated on current lifestyle changes and management with inclusion of exercise and diet 
modification. It was discussed whether she would like to increase or add on another oral 
medication; or if she would like to start daily dosing of a basal rate insulin. Due to her 10-
year history of diabetes mellitus, age of 60 years and possible declining beta cell function, 
basal rate insulin was recommended as first line therapy. D. was very agreeable to starting 
a basal rate of insulin at this time. She was instructed to continue her metformin at 500mg 
BID and to start nightly Glargine at 5units. She is going to check her sugars twice daily in 
the morning and then at night, and keep a log along with pertinent foods and comments 
that surround either high or low blood sugars. She is going to increase her Glargine by 1 
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unit every 2 days if her blood sugars remain above 150mg/dL. She was educated on the 
signs and symptoms of hypoglycemia and how to manage at home. I will plan to see her 
back in the clinic in 1 week for an evaluation of her management and a recheck of a fasting 
blood sugar. It was discussed that she should be seen by a primary more often and a Hgb 
A1C monitoring at least every 3 months until we are at a more stable control, if she does 
not have an appointed primary she is welcome to establish with myself. She was advised to 
return to the clinic sooner if she has any increasing symptoms or acute changes. D. 
verbalized an understanding and was agreeable to the plan of care.  
 
 
 
 
